| Trial ID: | L5938 |
| Source ID: | NCT05050500
|
| Associated Drug: |
Dapagliflozin 10mg/Tab
|
| Title: |
The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Myocardial Infarction|Diabete Type 2|Glucose Intolerance
|
| Interventions: |
DRUG: Dapagliflozin 10mg/Tab|DRUG: Placebo
|
| Outcome Measures: |
Primary: MACE events, To assess the occurence of myocardial infarction, stroke and death from cardiovascular causes in post-infarction patients during the follow-up time., 6 months|Left ventricular ejection fraction,left ventricle end-systolic volume (LVESV), and left ventricular end-diastolic volume, Evaluate baseline left ventricular ejection fraction (LVEF) and left ventricular end- diastolic volume(LVEDV) in post-MI patients and 6 months of treatment., 6 months|Post-infarction angina, Evaluate the post-infarction angina occurence in both groups, 6 months|The rate of heart failure occurrence, Assess the rate of new-onset heart failure during the study follow-up., 6 months |
|
| Sponsor/Collaborators: |
Sponsor: Qingdao Central Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
300
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2023-05-08
|
| Completion Date: |
2026-01-30
|
| Results First Posted: |
|
| Last Update Posted: |
2023-09-21
|
| Locations: |
Mengmei Li, Qingdao, Shandong, 266042, China
|
| URL: |
https://clinicaltrials.gov/show/NCT05050500
|
